AMGEN, INC.

Lobbying client · District of Columbia · filed 2026 to 2026

Biopharmaceutical company

$50,000 Reported spend

2 Filings counted

1 Firms hired

4 Bills named

Spend is reported income plus in-house expenses across 2 filings. Everything on this page is grouped by the client's LDA id (73362), not by name.

Firms hired 1

AVENUE SOLUTIONS $50,000 2 filings

Bills named in these filings 4

S 5459
Biosimilars Access and Affordability Act

1 filing
HR 4299
Protecting Patient Access to Cancer and Complex Therapies Act

1 filing
HR 5526
Biosimilar Red Tape Elimination Act

1 filing
S 1954
Biosimilar Red Tape Elimination Act

1 filing

Reported by year 1 year

2026 $50,000 2 filings

Issues lobbied 1

Medicare/Medicaid 2

The count is how many filings named that issue area. A filing reports one lump figure covering every issue on it, so the money above cannot be split between them.

Agencies and chambers lobbied 2

HOUSE OF REPRESENTATIVES 1
SENATE 1

Recent filings 2 total

Q2

AVENUE SOLUTIONS

2nd Quarter (Apr 1 - June 30) 2026 · House · Senate · $50,000 income · posted Jul 20, 2026

View → RR

AVENUE SOLUTIONS

2nd Quarter (Apr 1 - June 30) 2026 · posted Jun 1, 2026

View →

Source: federal Lobbying Disclosure Act filings, synced daily. Money is self-reported by the filer and often rounded. Lobbying is legal, disclosed activity.